PTC
KYNB

Philadelphia Trust Company’s Kyntra Bio KYNB Stock Holding History

Philadelphia Trust Company’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,731
Closed -$7.58M – 229
2021
Q1 		$7.58M Buy
8,731
+383
+5% +$408K 0.58% 43
2020
Q4 		$7.74M Buy
8,348
+7,532
+923% +$7.92M 0.63% 42
2020
Q3 		$839K Buy
+816
New +$878K 0.08% 117

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Philadelphia Trust Company's KYNB Position: Q2 2021 in Review

Philadelphia Trust Company sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 8,731 shares — an estimated $7.58M sold.

Philadelphia Trust Company first reported a position in KYNB in Q3 2020 and held it in 3 quarters. The position peaked at $7.74M in Q4 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Philadelphia Trust Company reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Philadelphia Trust Company sold 8,731 Kyntra Bio shares in Q2 2021, an estimated $7.58M.
  • Philadelphia Trust Company first reported a position in Kyntra Bio in Q3 2020 and held it in 3 quarters.
  • Philadelphia Trust Company's Kyntra Bio position peaked at $7.74M in Q4 2020.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Philadelphia Trust Company's 13F filing for Q2 2021, filed 13 Aug 2021.